We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

President Donald Trump’s executive order imposing a 10% tariff on Chinese imports is likely to drive up the cost of generic drugs in the United States and exacerbate drug shortages, experts say. About ...

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...